Napabucasin

Drug Profile

Napabucasin

Alternative Names: BB 608; BBI 608 DP1; BBI 608 DP2A; BBI-608; DP1; DP2A

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Boston Biomedical
  • Developer Boston Biomedical; Sumitomo Dainippon Pharma
  • Class Antineoplastics; Furans; Naphthoquinones; Small molecules
  • Mechanism of Action Beta catenin inhibitors; Cell death stimulants; STAT3 transcription factor inhibitors; Stem cell inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer; Gastric cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Colorectal cancer; Gastric cancer; Non-small cell lung cancer; Pancreatic cancer
  • Phase I/II Glioblastoma; Hepatocellular carcinoma; Mesothelioma; Solid tumours
  • Phase I Haematological malignancies
  • No development reported Gastrointestinal cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Gastrointestinal-cancer(Combination therapy, Late-stage disease) in Canada (PO, Capsule)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Gastrointestinal-cancer(Combination therapy, Late-stage disease) in USA (PO, Capsule)
  • 07 Jul 2017 Boston Biomedical terminates the phase III CanStem43L trial due to change of treatment landscape and evolving standard of care in Non-small cell lung cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA and Spain (PO) (NCT02826161)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top